WO2003020889A2 - Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules - Google Patents
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules Download PDFInfo
- Publication number
- WO2003020889A2 WO2003020889A2 PCT/US2002/027393 US0227393W WO03020889A2 WO 2003020889 A2 WO2003020889 A2 WO 2003020889A2 US 0227393 W US0227393 W US 0227393W WO 03020889 A2 WO03020889 A2 WO 03020889A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amines
- receptor
- alkyl
- immune response
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 155
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 title claims abstract description 153
- 230000028993 immune response Effects 0.000 title claims abstract description 70
- 239000003607 modifier Substances 0.000 title claims abstract description 61
- 210000004027 cell Anatomy 0.000 claims description 124
- -1 imidazoquinoline amines Chemical class 0.000 claims description 101
- 102000009410 Chemokine receptor Human genes 0.000 claims description 59
- 108050000299 Chemokine receptor Proteins 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 230000014509 gene expression Effects 0.000 claims description 46
- 102000004127 Cytokines Human genes 0.000 claims description 38
- 108090000695 Cytokines Proteins 0.000 claims description 38
- 210000004443 dendritic cell Anatomy 0.000 claims description 36
- 239000000556 agonist Substances 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 229940124669 imidazoquinoline Drugs 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 32
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims description 31
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 25
- 150000001412 amines Chemical class 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 22
- 102000008237 Toll-Like Receptor 6 Human genes 0.000 claims description 20
- 108010060826 Toll-Like Receptor 6 Proteins 0.000 claims description 20
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims description 20
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 20
- 238000000684 flow cytometry Methods 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 230000004083 survival effect Effects 0.000 claims description 18
- 230000030741 antigen processing and presentation Effects 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 14
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical class NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims description 13
- QOOXNMYDCWUEHW-UHFFFAOYSA-N [1,3]oxazolo[4,5-h]quinolin-2-amine Chemical class C1=CC=NC2=C(OC(N)=N3)C3=CC=C21 QOOXNMYDCWUEHW-UHFFFAOYSA-N 0.000 claims description 13
- 238000002965 ELISA Methods 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 11
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 10
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000012678 infectious agent Substances 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 210000005170 neoplastic cell Anatomy 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000016396 cytokine production Effects 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000004296 naive t lymphocyte Anatomy 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 238000000636 Northern blotting Methods 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 8
- 230000000069 prophylactic effect Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 125000000217 alkyl group Chemical group 0.000 description 142
- 125000004432 carbon atom Chemical group C* 0.000 description 141
- 229910052736 halogen Inorganic materials 0.000 description 61
- 229910052739 hydrogen Inorganic materials 0.000 description 61
- 239000001257 hydrogen Substances 0.000 description 60
- 125000003342 alkenyl group Chemical group 0.000 description 55
- 125000001424 substituent group Chemical group 0.000 description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 37
- 150000002367 halogens Chemical class 0.000 description 35
- 125000001072 heteroaryl group Chemical group 0.000 description 33
- 125000003545 alkoxy group Chemical group 0.000 description 30
- 125000000623 heterocyclic group Chemical group 0.000 description 26
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 16
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 102000003814 Interleukin-10 Human genes 0.000 description 13
- 108090000174 Interleukin-10 Proteins 0.000 description 13
- 150000002431 hydrogen Chemical class 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 12
- 239000002609 medium Substances 0.000 description 10
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102000006992 Interferon-alpha Human genes 0.000 description 7
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108010002386 Interleukin-3 Proteins 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 4
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 0 *c1nc(c(N)nc2c3ccc(I)c2)c3[n]1*=C Chemical compound *c1nc(c(N)nc2c3ccc(I)c2)c3[n]1*=C 0.000 description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VFTLXHXYGQSOEN-UHFFFAOYSA-N 1h-imidazo[4,5-b][1,8]naphthyridine Chemical compound C1=CN=C2NC3=NC=NC3=CC2=C1 VFTLXHXYGQSOEN-UHFFFAOYSA-N 0.000 description 2
- HLFGXPKPTDQYBN-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1N=C2C=CC=CC2=C2C1NCN2 HLFGXPKPTDQYBN-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000004965 chloroalkyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 101100481584 Mus musculus Tlr1 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 206010057179 Toxoplasma infections Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 102000045734 human CCL20 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464421—Receptors for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003525593A JP2005501550A (en) | 2001-08-30 | 2002-08-28 | Maturation of plasmacytoid dendritic cells using immune response modifier molecules |
MXPA04001972A MXPA04001972A (en) | 2001-08-30 | 2002-08-28 | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules. |
EP02766145A EP1427445A4 (en) | 2001-08-30 | 2002-08-28 | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
CA002458876A CA2458876A1 (en) | 2001-08-30 | 2002-08-28 | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31614401P | 2001-08-30 | 2001-08-30 | |
US60/316,144 | 2001-08-30 | ||
US37017702P | 2002-04-05 | 2002-04-05 | |
US60/370,177 | 2002-04-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003020889A2 true WO2003020889A2 (en) | 2003-03-13 |
WO2003020889A3 WO2003020889A3 (en) | 2004-01-22 |
Family
ID=26980262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/027393 WO2003020889A2 (en) | 2001-08-30 | 2002-08-28 | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030133913A1 (en) |
EP (1) | EP1427445A4 (en) |
JP (1) | JP2005501550A (en) |
CA (1) | CA2458876A1 (en) |
MX (1) | MXPA04001972A (en) |
WO (1) | WO2003020889A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6747040B2 (en) | 1997-12-11 | 2004-06-08 | 3M Innovative Properties Company | Imidazonaphthyridines |
US6784188B2 (en) | 1999-06-10 | 2004-08-31 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6797718B2 (en) | 2002-06-07 | 2004-09-28 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US6818650B2 (en) | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
WO2005012509A2 (en) * | 2003-08-04 | 2005-02-10 | Imba-Institut Für Molekulare Biotechnologie Gmbh | Method for immunotherapy of tumors |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
US6921826B2 (en) | 2000-12-08 | 2005-07-26 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US6949649B2 (en) | 2000-12-08 | 2005-09-27 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US6953804B2 (en) | 2000-12-08 | 2005-10-11 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US6989389B2 (en) | 2000-12-08 | 2006-01-24 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US7078523B2 (en) | 2000-12-08 | 2006-07-18 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7115622B2 (en) | 2000-12-08 | 2006-10-03 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
JP2007503268A (en) * | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | Delivery of immune response modifying compounds |
CN100398641C (en) * | 2003-10-17 | 2008-07-02 | 高斌 | Dendritic cell culturing method and kit |
US7427629B2 (en) | 2002-08-15 | 2008-09-23 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
US7598382B2 (en) | 2002-12-20 | 2009-10-06 | Coley Pharmaceutical Group, Inc. | Aryl substituted imidazoquinolines |
US7696159B2 (en) | 2003-03-25 | 2010-04-13 | Graceway Pharmaceuticals, Llc | Treatment for basal cell carcinoma |
US7879810B2 (en) | 1994-07-15 | 2011-02-01 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
WO2013013055A1 (en) | 2011-07-21 | 2013-01-24 | Rubigo Therapeutics, Inc. | System for drug delivery and monitoring |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
JP2014170003A (en) * | 2008-07-25 | 2014-09-18 | Cellestis Ltd | Diagnostic method |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
WO2015095143A1 (en) | 2013-12-16 | 2015-06-25 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
WO2018057447A1 (en) * | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
EP3578642A4 (en) * | 2017-01-31 | 2020-07-29 | Quratis Inc. | Plasmacytoid dendritic cells having immune tolerance, and method for producing same |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
ES2541132T3 (en) * | 2002-02-22 | 2015-07-16 | Meda Ab | Method to reduce and treat UV-B-induced immunosuppression |
US7375180B2 (en) * | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
EP1605943A4 (en) * | 2003-03-07 | 2008-01-16 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines |
AU2004220465A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
US7699057B2 (en) * | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
AR044466A1 (en) * | 2003-06-06 | 2005-09-14 | 3M Innovative Properties Co | PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS |
WO2004110991A2 (en) * | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
CA2534313C (en) * | 2003-08-05 | 2013-03-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
TW200510412A (en) * | 2003-08-12 | 2005-03-16 | 3M Innovative Properties Co | Oxime substituted imidazo-containing compounds |
CA2535338C (en) * | 2003-08-14 | 2013-05-28 | 3M Innovative Properties Company | Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers |
JP2007504145A (en) * | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Immunostimulatory combinations and treatments |
CA2536136C (en) | 2003-08-27 | 2012-10-30 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
JP2007504269A (en) | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Method for treating CD5 + B cell lymphoma |
WO2005027841A2 (en) * | 2003-09-16 | 2005-03-31 | University Of North Carolina At Chapel Hill | Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease |
EP1664342A4 (en) * | 2003-09-17 | 2007-12-26 | 3M Innovative Properties Co | Selective modulation of tlr gene expression |
US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
NZ546274A (en) | 2003-10-03 | 2009-12-24 | 3M Innovative Properties Co | Pyrazolopyridines and analags thereof |
JP5043435B2 (en) | 2003-10-03 | 2012-10-10 | スリーエム イノベイティブ プロパティズ カンパニー | Alkoxy substituted imidazoquinolines |
AU2004285575A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
CN1906193A (en) * | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | Oxime substituted imidazo ring compounds |
AU2004291122A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
EP1686992A4 (en) * | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
WO2005076783A2 (en) * | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
CA2552101A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
WO2005066169A2 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
AU2005222995B2 (en) * | 2004-03-15 | 2010-08-26 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
JP2008505857A (en) * | 2004-04-28 | 2008-02-28 | スリーエム イノベイティブ プロパティズ カンパニー | Compositions and methods for mucosal vaccination |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
EP1765348B1 (en) * | 2004-06-18 | 2016-08-03 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US20060045886A1 (en) * | 2004-08-27 | 2006-03-02 | Kedl Ross M | HIV immunostimulatory compositions |
AU2005282523A1 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1H imidazo ring systems and methods |
AU2005282726B2 (en) * | 2004-09-02 | 2011-06-02 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
JP2008515928A (en) * | 2004-10-08 | 2008-05-15 | スリーエム イノベイティブ プロパティズ カンパニー | Adjuvants for DNA vaccines |
US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
CA2592897A1 (en) * | 2004-12-30 | 2006-07-13 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
JP2008526765A (en) * | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | Treatment of skin metastases |
AU2006338521A1 (en) | 2005-02-09 | 2007-10-11 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
CA2597446A1 (en) | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
JP2008530113A (en) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods |
AU2006216686A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
AU2006216799A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
JP2008531567A (en) | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Hydroxyalkyl-substituted imidazoquinoline compounds and methods |
US8178677B2 (en) | 2005-02-23 | 2012-05-15 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
MX2007011112A (en) | 2005-03-14 | 2007-11-07 | Graceway Pharmaceuticals Llc | Method of treating actinic keratosis. |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
US7943636B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
JP2008539252A (en) * | 2005-04-25 | 2008-11-13 | スリーエム イノベイティブ プロパティズ カンパニー | Immune activation composition |
WO2007029689A1 (en) * | 2005-09-08 | 2007-03-15 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
EA200800782A1 (en) | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | AMIDA AND CARBAMATE DERIVATIVES N- {2- [4-AMINO-2- (ETOXIMETHYL) -1H-IMIDAZOLO [4,5-c] QUINOLIN-1-IL] -1,1-DIMETHYLETHYL} METHANE SULFONAMIDE AND METHODS |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US20090297540A1 (en) * | 2005-10-21 | 2009-12-03 | Andrew Mellor | Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof |
JP5247458B2 (en) | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007106854A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
US8178539B2 (en) | 2006-09-06 | 2012-05-15 | 3M Innovative Properties Company | Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
HUE033901T2 (en) | 2010-08-17 | 2018-01-29 | 3M Innovative Properties Co | Lipidated immune response modifier compound compositions, formulations, and methods |
JP6460789B2 (en) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker |
BR112013031039B1 (en) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate |
CN105911292B (en) * | 2016-05-19 | 2018-06-26 | 深圳市衍生生物科技有限公司 | For combinatory analysis CD11c+CD11b+The kit and method of DC subgroups and its differentiation degree and function |
CA3088957A1 (en) * | 2017-01-17 | 2018-07-26 | Tufts Medical Center, Inc. | Adoptive transfer of plasmacytoid dendritic cells to prevent or treat ocular diseases and conditions |
KR101893886B1 (en) * | 2017-01-31 | 2018-08-31 | 주식회사 큐라티스 | Pharmaceutical composition for preventing or treating autoimmune disease and the method for preparing thereof |
KR20180089224A (en) * | 2017-01-31 | 2018-08-08 | 주식회사 큐라티스 | Pharmaceutical composition for preventing or treating hypersensitivity immune disease and the method for preparing thereof |
EP3728255B1 (en) | 2017-12-20 | 2022-01-26 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
CN109797209B (en) * | 2019-01-04 | 2021-07-16 | 中国人民解放军第二军医大学 | Specific biomarker of dendritic cells and/or chemotactic states and functions thereof |
KR102003958B1 (en) * | 2019-04-08 | 2019-07-25 | 주식회사 큐라티스 | Pharmaceutical composition for preventing or treating hypersensitivity immune disease and the method for preparing thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017279A1 (en) * | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
WO2000047719A2 (en) * | 1999-02-11 | 2000-08-17 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US246194A (en) * | 1881-08-23 | Waffle-iron | ||
US394026A (en) * | 1888-12-04 | Carpenter s trestle | ||
US246749A (en) * | 1881-09-06 | Washing-machine | ||
US246193A (en) * | 1881-08-23 | Sewer-trap | ||
US1104764A (en) * | 1911-06-30 | 1914-07-28 | Mary A Baird | Flat-iron holder. |
US3314941A (en) * | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
ZA848968B (en) * | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
US4698338A (en) * | 1986-02-19 | 1987-10-06 | Eli Lilly And Company | 7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins |
US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5756747A (en) * | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5037986A (en) * | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
ES2071340T3 (en) * | 1990-10-05 | 1995-06-16 | Minnesota Mining & Mfg | PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS. |
US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5175296A (en) * | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
JPH09500128A (en) * | 1993-07-15 | 1997-01-07 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Imidazo [4,5-c] pyridin-4-amine |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2194761C (en) * | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
US5693811A (en) * | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
ES2232871T3 (en) * | 1996-07-03 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | NEW DERIVATIVES OF PURINA. |
US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
JP4101302B2 (en) * | 1997-01-09 | 2008-06-18 | テルモ株式会社 | Novel amide derivatives and synthetic intermediates |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1003531B1 (en) * | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
US6329381B1 (en) * | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
UA67760C2 (en) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
CA2361936C (en) * | 1999-01-08 | 2009-06-16 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6083969A (en) * | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
US6376669B1 (en) * | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US20020055517A1 (en) * | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
-
2002
- 2002-08-28 JP JP2003525593A patent/JP2005501550A/en active Pending
- 2002-08-28 EP EP02766145A patent/EP1427445A4/en not_active Withdrawn
- 2002-08-28 MX MXPA04001972A patent/MXPA04001972A/en not_active Application Discontinuation
- 2002-08-28 CA CA002458876A patent/CA2458876A1/en not_active Abandoned
- 2002-08-28 WO PCT/US2002/027393 patent/WO2003020889A2/en active Application Filing
- 2002-08-28 US US10/229,829 patent/US20030133913A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017279A1 (en) * | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
WO2000047719A2 (en) * | 1999-02-11 | 2000-08-17 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
Non-Patent Citations (8)
Title |
---|
AHONEN C.L. ET AL.: 'Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848' CELL IMMUNOL. vol. 197, no. 1, October 1999, pages 62 - 72, XP000939324 * |
BURNS R.P. ET AL.: 'The imidazoquinolines, imiquimod and R-848, induced functional, but not phenotypic, maturation of human epidermal langerhans' cells' CLIN. IMMUNOL. vol. 94, no. 1, January 2000, pages 13 - 23, XP002964628 * |
GRABBE S. ET AL.: 'R848 activates immature dendritic cells in vitro and modulates the sensitization and effector phase of murine contact hypersensitivity (CHS) responses' J. INVEST. DERMATOL. vol. 117, no. 2, August 2001, page 447, ABSTRACT NO.346, XP002964629 * |
GUNZER M. ET AL.: 'The immune response modifier R-848 in a Th1-polarizing agent for immature but not precursor murine dendritic cells' ARCH. DERMATOL. RES. vol. 293, no. 1-2, February 2001, page 54, ABSTRACT NO.P45, XP002964630 * |
MILLER R.L. ET AL.: 'Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod' ANTIVIRAL RES. vol. 44, no. 1, November 1999, pages 31 - 42, XP002964632 * |
See also references of EP1427445A2 * |
SUZUKI H. ET AL.: 'Imiquimod, a topical immune response modifier, induces migration of langerhans cells' J. INVEST. DERMATOLOGY vol. 114, no. 1, January 2000, pages 135 - 141, XP002964631 * |
VASILAKOS J.P. ET AL.: 'Adjuvant activities of immune response modifier R-848: comparison with CpG ODN' CELL IMMUNOL. vol. 204, no. 1, 2000, pages 64 - 74, XP001037913 * |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879810B2 (en) | 1994-07-15 | 2011-02-01 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6894165B2 (en) * | 1997-12-11 | 2005-05-17 | 3M Innovative Properties Company | Imidazonaphthyridines |
US6747040B2 (en) | 1997-12-11 | 2004-06-08 | 3M Innovative Properties Company | Imidazonaphthyridines |
US7335773B2 (en) | 1997-12-11 | 2008-02-26 | Graceway Pharmaceuticals, Llc | Intermediates for imidazonaphthyridines |
US6797716B2 (en) | 1997-12-11 | 2004-09-28 | 3M Innovative Properties Company | Imidazonaphthyridines |
US7678918B2 (en) | 1997-12-11 | 2010-03-16 | 3M Innovative Properties Company | Intermediates for imidazonaphthyridines |
US6949646B2 (en) | 1997-12-11 | 2005-09-27 | 3M Innovative Properties Co. | Imidazonaphthyridines |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US6784188B2 (en) | 1999-06-10 | 2004-08-31 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
US7132429B2 (en) | 2000-12-08 | 2006-11-07 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6921826B2 (en) | 2000-12-08 | 2005-07-26 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US7276515B2 (en) | 2000-12-08 | 2007-10-02 | Coley Pharmaceutical Group, Inc. | Thioether substituted imidazoquinolines |
US6949649B2 (en) | 2000-12-08 | 2005-09-27 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US7288550B2 (en) | 2000-12-08 | 2007-10-30 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6953804B2 (en) | 2000-12-08 | 2005-10-11 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US6989389B2 (en) | 2000-12-08 | 2006-01-24 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US7078523B2 (en) | 2000-12-08 | 2006-07-18 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7214675B2 (en) | 2000-12-08 | 2007-05-08 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7115622B2 (en) | 2000-12-08 | 2006-10-03 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6924293B2 (en) | 2001-12-21 | 2005-08-02 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6888000B2 (en) | 2001-12-21 | 2005-05-03 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US7125890B2 (en) | 2002-06-07 | 2006-10-24 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US6797718B2 (en) | 2002-06-07 | 2004-09-28 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US7427629B2 (en) | 2002-08-15 | 2008-09-23 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
EP2269632A2 (en) | 2002-08-15 | 2011-01-05 | 3M Innovative Properties Co. | Immunostimulatory compositions and methods of stimulating an immune response |
US6818650B2 (en) | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
US7112677B2 (en) | 2002-09-26 | 2006-09-26 | 3M Innovative Properties Company | 1H-imidazo dimers |
US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US7598382B2 (en) | 2002-12-20 | 2009-10-06 | Coley Pharmaceutical Group, Inc. | Aryl substituted imidazoquinolines |
US10105426B2 (en) | 2002-12-30 | 2018-10-23 | Trustees Of Dartmouth College | Immunostimulatory combinations |
EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
US7696159B2 (en) | 2003-03-25 | 2010-04-13 | Graceway Pharmaceuticals, Llc | Treatment for basal cell carcinoma |
US8835394B2 (en) | 2003-03-25 | 2014-09-16 | Medicis Pharmaceutical Corporation | Treatment for basal cell carcinoma |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
WO2005012509A3 (en) * | 2003-08-04 | 2005-04-21 | Josef Penninger | Method for immunotherapy of tumors |
JP4939219B2 (en) * | 2003-08-04 | 2012-05-23 | イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Methods for tumor immunotherapy |
US8124067B2 (en) * | 2003-08-04 | 2012-02-28 | Imba-Institute Fur Molekulre Biotechnologie Gmbh | Method for immunotherapy of tumors |
CN1845988B (en) * | 2003-08-04 | 2011-09-14 | 分子生物技术院有限公司 | Method for immunotherapy of tumors |
WO2005012509A2 (en) * | 2003-08-04 | 2005-02-10 | Imba-Institut Für Molekulare Biotechnologie Gmbh | Method for immunotherapy of tumors |
JP2007501607A (en) * | 2003-08-04 | 2007-02-01 | イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Methods for tumor immunotherapy |
JP2007503268A (en) * | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | Delivery of immune response modifying compounds |
CN100398641C (en) * | 2003-10-17 | 2008-07-02 | 高斌 | Dendritic cell culturing method and kit |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US10071156B2 (en) | 2005-02-04 | 2018-09-11 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
JP2014170003A (en) * | 2008-07-25 | 2014-09-18 | Cellestis Ltd | Diagnostic method |
WO2013013055A1 (en) | 2011-07-21 | 2013-01-24 | Rubigo Therapeutics, Inc. | System for drug delivery and monitoring |
WO2015095143A1 (en) | 2013-12-16 | 2015-06-25 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
EP3083946A4 (en) * | 2013-12-16 | 2017-08-16 | The University of North Carolina at Chapel Hill | Depletion of plasmacytoid dendritic cells |
US9914780B2 (en) | 2013-12-16 | 2018-03-13 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
US10214587B2 (en) | 2013-12-16 | 2019-02-26 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
US11028175B2 (en) | 2013-12-16 | 2021-06-08 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
WO2018057447A1 (en) * | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
EP3578642A4 (en) * | 2017-01-31 | 2020-07-29 | Quratis Inc. | Plasmacytoid dendritic cells having immune tolerance, and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
MXPA04001972A (en) | 2005-02-17 |
CA2458876A1 (en) | 2003-03-13 |
US20030133913A1 (en) | 2003-07-17 |
WO2003020889A3 (en) | 2004-01-22 |
JP2005501550A (en) | 2005-01-20 |
EP1427445A4 (en) | 2006-09-06 |
EP1427445A2 (en) | 2004-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003020889A2 (en) | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules | |
Romagnani | Biology of human TH 1 and TH 2 cells | |
US6558951B1 (en) | Maturation of dendritic cells with immune response modifying compounds | |
Romagnani | Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology | |
Suzuki et al. | Inhibitory CD8+ T cells in autoimmune disease | |
Thanhäuser et al. | The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells | |
Hajoui et al. | Synthesis of IL-13 by human B lymphocytes: regulation and role in IgE production | |
KR20090126329A (en) | Cd4+cd25+ regulatory t cells from human blood | |
EP1719511A2 (en) | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof | |
JP2006312640A (en) | Activation of t cell | |
Sinnott et al. | Direct TLR-2 costimulation unmasks the proinflammatory potential of neonatal CD4+ T cells | |
US20140234353A1 (en) | Methods of obtaining antigen-specific t cell populations | |
WO2015199402A1 (en) | Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same | |
JP6283347B2 (en) | Method for producing mature dendritic cell population | |
Castellaneta et al. | Identification and characterization of intestinal Peyer's patch interferon-α producing (plasmacytoid) dendritic cells | |
AU2002329892A1 (en) | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules | |
JP5717116B2 (en) | Method for preparing antigen-specific human Th17 cells | |
Beissert et al. | Differential regulation of epidermal cell tumor-antigen presentation by IL-1α and IL-1β | |
Fischer et al. | Characterization of lymphokine-mediated activation of macrophages for antigen presentation: studies with long-term cultured bone marrow-derived macrophages and cloned T cells | |
Hain et al. | Stimulation of rheumatoid synovial and blood T cells and lines by synovial fluid and interleukin-2: characterization of clones and recognition of a co-stimulatory effect | |
Iwashita et al. | Potent stimuli combined with lipopolysaccaride and IFNγ may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells | |
Smits et al. | How to deal with polarized Th2 cells: exploring the Achilles’ heel | |
JP2024512814A (en) | Method for producing regulatory T cells by culturing regulatory T cells obtained from umbilical cord blood | |
El Husseiny et al. | The Effect of Monophosphoryl Lipid A on Maturation of DCs from Patients with Acute Myeloid Leukaemia | |
Herreros et al. | Lymphoma microenvironment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2458876 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001972 Country of ref document: MX Ref document number: 2002329892 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002766145 Country of ref document: EP Ref document number: 2003525593 Country of ref document: JP Ref document number: 453/CHENP/2004 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002766145 Country of ref document: EP |